Science

Precision Therapeutics for APOE4-Driven Neurovascular Disease

6M+ Americans living with Alzheimer's today
16M Projected U.S. cases by 2050
$3B Estimated annual revenue suppressed by ARIA risk
700K APOE4 AD patients at high ARIA risk (near-term market)

PebRx is a biotechnology company developing precision therapeutics and diagnostics designed to address neurovascular inflammation in Alzheimer's disease and related neurodegenerative disorders.

The company's lead therapeutic candidate, BRI-Series, is designed to reduce neurovascular inflammation while preserving normal physiological signaling.

PebRx's platform is built on emerging evidence that APOE4-driven inflammatory lipid signaling is a central driver of vascular injury, blood-brain barrier dysfunction, and disease progression.

The company's long-term vision is to establish a new category of precision neuroinflammatory therapeutics capable of improving disease modification, vascular resilience, and treatment safety in genetically defined patient populations.

Our Focus

PebRx's scientific platform is centered on our neuroinflammation platform, addressing inflammatory lipid signaling and bioactive lipid production in the brain. Research has demonstrated links between cPLA2 activation and:

  • APOE4-associated Alzheimer's disease (AD)
  • Cerebral amyloid angiopathy (CAA)
  • Amyloid-related imaging abnormalities (ARIA)
  • Neurovascular inflammation associated with anti-amyloid therapies
  • Blood-brain barrier (BBB) disruption
  • Tau pathology
  • Vascular inflammation
  • Synaptic dysfunction
  • Microbleed burden in APOE4 disease models

Why It Matters

  • APOE4 is common and high-impact. Up to 25% of the U.S. population carries the APOE4 allele, the strongest common genetic risk factor.
  • Pathology precedes symptoms by decades. Brain changes begin 15–20+ years before cognitive symptoms appear, underscoring the case for early, biomarker-driven intervention.
  • Anti-amyloid therapies have transformed care, but gaps remain
  • APOE4 carriers bear disproportionate risk from current therapeutics. This population faces higher rates of vascular injury (CAA) and treatment-related complications, including ARIA, on anti-amyloid therapy.
  • No approved therapy targets CAA or ARIA

A Precision Neurovascular Strategy

PebRx is pursuing a differentiated therapeutic strategy designed to intervene upstream in the inflammatory cascade rather than broadly suppress inflammation downstream. The goal is not to eliminate cPLA2 activity entirely, but to reduce its pathological overactivation in APOE4 disease.

  • Reduce pathological inflammatory activation
  • Improve vascular resilience
  • Mitigate neurovascular injury
  • Complement anti-amyloid therapies
  • Expand treatment eligibility among high-risk APOE4 carriers

Integrated Therapeutic & Diagnostic Platform

In parallel with therapeutic development, PebRx is advancing PET imaging biomarkers, including 18F-FDHA (PUFA metabolism) and 18F-AA (neuroinflammation), designed to quantify inflammatory lipid metabolism and pathway activation in vivo.

  • Precision patient selection
  • Biomarker-guided clinical development
  • Pharmacodynamic monitoring
  • Earlier disease detection and intervention

BRI-50460 is designed as a proprietary, potent, BBB-penetrant, and selective small molecule with >100-fold selectivity over other phospholipase homologues.